Argus raised the firm’s price target on Cardinal Health (CAH) to $189 from $185 and keeps a Buy rating on the shares. The company is executing well with all of its segments delivering double digit profit growth in Q4 and FY25, the analyst tells investors in a research note. Shares are trading below Cardinal’s peers, but the recent weakness in the stock presents a buying opportunity, Argus adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health CEO sells $16.04M in common stock
- Cardinal Health Secures $1 Billion in Notes Sale
- Cardinal Health price target raised to $203 from $197 at Baird
- Cardinal Health price target raised to $185 from $183 at Wells Fargo
- Cardinal Health’s Growth Potential: Buy Rating Reaffirmed Amid Strong Pharma Performance and Strategic Focus